Tucuvi

What Is Tucuvi?

Picture a cardiology nurse in Barcelona on a Monday morning. Forty patients were discharged last week after heart-failure admissions, and each needs a call to check weight, breathlessness and medication. She has time for perhaps ten. The rest wait until something goes wrong. This is the gap Tucuvi exists to close.

Tucuvi is a Madrid-based company whose voice agent, LOLA, phones patients, asks protocol-driven questions and escalates to a human team when an answer looks worrying. It is a patient-facing agent, not a note-taking scribe, and that makes it a different tool from Nabla or Tandem Health. Those products listen to a consultation. LOLA starts the conversation.

The legal entity is Tucuvi Care, S.L., with its registered office on Calle Hermosilla in Madrid. The company was constituted in September 2019 and is led by CEO María González Manso and CTO Marcos Rubio. In January 2026 it announced a $20M (about EUR 17M) Series A, co-led by Cathay Innovation and Kfund's Leadwind fund, with Frontline Ventures, Seaya Ventures and Shilling returning. Around 31 staff were reported at the time of the round.

One ownership note matters for US buyers. Tucuvi Health, Inc., in New York, is a subsidiary, and Tucuvi's own US messaging terms name Tucuvi Care, S.L. as its parent. The parent is Spanish. Tucuvi sits in EuropeanStack's Healthcare AI category.

Key Features

Autonomous protocol-based calls

LOLA conducts phone conversations following clinical protocols, and Tucuvi lists 60+ configurable ones. Examples include COPD, heart failure, asthma, diabetes, breast and prostate cancer follow-up, post-discharge checks and vaccination campaigns. A hospital configures the protocol, LOLA makes the calls, and structured results return to the care team.

Scheduling and rescheduling

Appointment management is the highest-volume use case. Tucuvi's site cites one hospital network where LOLA handled more than 868,000 calls at a 77 percent autonomy rate and freed over 123,000 staff hours a year. Those figures are vendor-reported and refer to a single customer, so treat them as an illustration rather than a benchmark.

Escalation to humans

LOLA is designed to hand over. When a patient reports symptoms that cross a protocol threshold, or when the conversation falls outside its scope, the case goes to clinical staff. Good escalation logic is the difference between a useful triage layer and a liability, and it is where a pilot should be tested hardest.

Medical device status

Tucuvi reports an EU MDR Class IIb marking for LOLA, published in July 2025 after an earlier Class I classification. It describes this as the first clinical voice AI recognised at that level in Europe. We could not independently check that superlative. Few voice agents in healthcare carry any device classification, so the marking is a meaningful signal.

Scale and customers

The homepage claims more than one million autonomous calls and 60+ healthcare organisations across Europe, the UK and the US. Named customers include Vall d'Hebron and Bellvitge hospitals, South Warwickshire NHS and pharmaceutical groups such as AstraZeneca, Bristol Myers Squibb and Johnson and Johnson. Spanish public hospitals are the anchor base.

Where it fits next to scribes

Ambient scribes and voice agents solve opposite ends of the care journey. A scribe such as Tandem Health shortens the paperwork after a visit. LOLA reaches patients between visits, when a missed medication or a creeping symptom would otherwise go unseen. Some hospitals will want both. The two do not compete for the same budget line, which is why we do not list Tucuvi as an alternative to any US scribe.

Support and integration

Tucuvi sells through a dedicated team, and we did not find public self-service documentation or a developer API. The site calls the platform fully interoperable but does not name EHR partners, so interoperability is something to test in a pilot rather than assume. Expect an implementation project, with protocols configured alongside your clinical leads, rather than a product you switch on in an afternoon.

Pricing

Tucuvi does not publish pricing. There is no pricing page, no free tier and no trial. Access starts with a demo, and the commercial model is a custom quote. We therefore list a single custom tier and cannot give a per-call or per-patient figure.

That is a real weakness for anyone budgeting. Scribes such as Tandem Health publish a free plan and a EUR 125 Pro price, and Corti lists usage-based rates. With Tucuvi, expect pricing to depend on call volume, the number of protocols and integration work. Ask for a pilot with a fixed scope and agree the success metrics, such as completed calls and escalation accuracy, up front.

Funding and Stability

Tucuvi is venture-backed and still young. Beyond the January 2026 Series A, earlier funding included about EUR 5M from Axis, the venture arm of Spain's ICO. The Spanish commercial register recorded a share capital increase in January 2026 that matches the round. In September 2026 Kfund's Spanish manager joined the board, which is normal after a round.

Investors are European: Cathay Innovation is based in Paris, and Kfund, Seaya and Frontline are European funds. We found no single controlling investor. For a hospital signing a multi-year contract, the practical question is runway, so ask about it directly.

EU Compliance & Privacy

Tucuvi is a Spanish company, so GDPR applies directly and EU customers contract with the Madrid entity. Its privacy policy says that because it operates in both the EU and the US, personal data is retained in the region of its origin, with Standard Contractual Clauses covering transfers.

The gap is specificity. Tucuvi does not name its hosting provider or region on public pages, so we have left the EU-hosting field blank rather than assert it. A Vanta trust centre exists, but we could not read it. Request the sub-processor list and the data processing agreement, and confirm where call audio and transcripts are stored.

Certifications are strong on paper. Tucuvi's homepage lists ISO 27001, ISO 13485, HIPAA and Spain's Esquema Nacional de Seguridad, plus CE marking as Software as a Medical Device. The Class IIb level comes from company announcements. We could not confirm a SOC 2 report on a public page, so we do not claim one. These are vendor claims. Voice calls with patients involve health data, which is special-category data under GDPR, so the data processing terms matter more than any badge.

Who It's Best For

Hospitals with chronic-care follow-up backlogs. If your teams cannot phone every discharged heart-failure or COPD patient, LOLA targets that bottleneck directly.

Health systems with heavy scheduling traffic. If rescheduling calls swamp the front desk, the autonomy rates Tucuvi reports are worth testing in a pilot.

Life-sciences companies running patient programmes. If you need adherence checks at scale, Tucuvi already works with several pharmaceutical groups.

Clinics that mainly need documentation help. If your problem is typing notes after consultations, choose a scribe such as Nabla or Tandem Health instead.

The Verdict

Tucuvi is a credible, regulated voice agent from a Spanish parent company, and it fills a niche that European scribes do not touch. The reported MDR Class IIb marking, the clinical references and the escalation design are real strengths. On the other side, the drawbacks are equally real. Pricing is opaque, hosting details are not public, public language support appears limited to English and Spanish, and EHR partners are not named. A voice agent can also mishear a symptom or record a wrong answer, so clinical teams must audit call summaries and review every escalation. Pilot it before scaling.

Frequently Asked Questions

What does Tucuvi's LOLA do?

LOLA is a clinical voice agent that phones patients, follows evidence-based protocols for follow-up, scheduling and medication checks, and escalates to human teams when needed. It is a patient-facing agent, not a consultation note scribe.

Is Tucuvi GDPR compliant?

Tucuvi Care, S.L. is a Spanish company in Madrid, so GDPR applies directly. Its privacy policy says data is retained in its region of origin, with Standard Contractual Clauses for transfers. The hosting provider is not named publicly.

How much does Tucuvi cost?

Tucuvi does not publish pricing. Contracts are scoped through a demo and sales conversation, so expect a custom quote based on protocols and call volume.

Is Tucuvi a regulated medical device?

Yes. Tucuvi reports an EU MDR Class IIb marking for LOLA, published in July 2025, after an earlier Class I classification. Its homepage also lists ISO 13485, ISO 27001, HIPAA and CE marking as Software as a Medical Device.

Does Tucuvi have a US entity?

Yes. Tucuvi Health, Inc. in New York is a subsidiary, and its own terms name Tucuvi Care, S.L. in Madrid as the parent. European customers contract with the Spanish company.